47 research outputs found
Coinheritance of HbD-Punjab/Ξ²+-thalassemia (IVSI+5 G-C) in patient with Gilbert's syndrome
Thalassemia and qualitative hemoglobinopathy are hereditary disorders of Hb synthesis that lead to change in the Hb conformation or a decrease in the synthesis of structurally normal Hb, and consequently, to erythron pathology. Many variants of Hb are unstable or have altered affinity for oxygen, and, in heterozygous form can be associated with clinical and hematological manifestations (hemolytic anemia, hypochromic microcytic anemia, erythrocytosis). HbD-Punjab [Ξ²121 (GH4) Glu β Gln; HBB: C.364G> C] is variant of Hb carrying the amino acid substitution in the 121 position of Ξ²-globin chain. In all cases reported so far, patients with HbD-Punjab/Ξ²+-thalassemia (IVSI+5 G-C) combination experienced typical thalassemia with hypochromic microcytosis. HbD-Punjab was detected by electrophoresis from 37 to 94% of total Hb. The article describes rare clinical case of the cohabitation of HbD-Punjab/Ξ²+-thalassemia (IVSI+5 G-C) in a patient with homozygous variant of Gilbert's syndrome observed in AS Loginov Moscow Clinical Scientific Center
CUTANEOUS MANIFESTATIONS OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Background: Angioimmunoblast T-cell lymphoma (AITL) is a rare T-cell lymphoproliferative disease that is accompanied by generalized lymphadenopathy, hepatosplenomegaly, intoxication symptoms and extranodal lesions. The extranodal manifestations of the disease frequently involve various skin changes. One of the first such manifestations is maculopapular rashes observed in about half of AITL patients and usually preceding the appearance of lymphadenopathy. Other forms of skin lesions accompany the disease considerably less frequently.Aim: To characterize the range of skin changes in patients suffering from AITL, to establish a correspondence between the nature of skin changes and their histological picture.Materials and methods: 54 AITL patients were being treated at the National Research Centre for Hematology from 2000 to 2017, with the male/female ratio being 30/24. The median age was 61 (29β81) years.Results: Changes in the skin were observed in 24 (44.4 %) of 54 AITL patients, out of whom 18 (75 %) and 6 (25 %) were male and female patients, respectively. Maculopapular rash was observed in 22 (91.7 %) out of 24 patients. The morphological and molecular investigations of skin biopsy specimens exhibiting maculopapular rash demonstrated nonspecific reactive changes. Patients with maculopapular rash demonstrated an increase in the level of total (polyclonal) IgE. Specific skin lesions detected in 8 (14.8 %) cases were represented by a βlivedo reticularisβ, focal skin hyperpigmentation, erythroderma, left eyelid tumour and tumour in 3, 2, 1, 1 and 1 cases, respectively.Conclusion: Maculopapular rash frequently observed in AITL patients is a reactive process not associated with a specific skin lesion. Specific skin lesions in AITL are much less common and can be represented by various forms. In some AITL cases, skin changes of the reactive and tumour nature can be simultaneously observed
Assessment of bone marrow biopsy in patients with masked polycythemia vera
Masked polycythemia vera (PV) is characterized by presence ot Jak2 mutation, specific morphological pattern in the bone marrow biopsy, and the lack demanding levels of Hb in accordance with criteria WHO, 2008 for PV. The purpose of this study was assessment of the pathomorphologic peculiarities of bone marrow biopsies in patients with masked PV. The group of 24 patients with masked PV was formed on the basis of morphological picture, clinical, laboratory and molecular data. Histological examination of bone marrow trephine biopsy in most cases showed hypercellular marrow 18/24 (75%) (age adujsted). Enlargement and rejuvenation of erythroid lineage was observed in 23/24 and 22/24 cases (95.9% and 91.7%). The histotopography of megakaryocytes in the majority of cases, 20/24 (83.3%) was characterized by discrete arrangement of megakaryocytes and forming intertrabecular loose clusters (3-16 cells). Typical for PV morphology of megakaryocytes was detected in the majority of cases, 19/24 (79.2%). There were 5/24 (20,8%) cases with characteristic features of essential thrombocythemia (ΠΠ’-like features). The grade of stroma fibrosis in all cases was MF-0. Morphological picture in bone marrow biopsy of patients with masked PV was characteristic for PV in most cases. However, in some cases of masked PV the morphology part of megakaryocytes was similar to essential thrombocythemia or pre-fibrotic/early stage of primary myelofibrosis.ΠΠ°ΡΠΊΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ ΠΈΡΡΠΈΠ½Π½Π°Ρ ΠΏΠΎΠ»ΠΈΡΠΈΡΠ΅ΠΌΠΈΡ (ΠΠ) ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΠΌΠΎΠΉ ΠΈΡΡΠΈΠ½Π½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΡΠΈΡΠ΅ΠΌΠΈΠΈ, Π΄Π»Ρ ΠΊΠΎΡΠΎΡΠΎΠΉ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΠΎ Π½Π°Π»ΠΈΡΠΈΠ΅ ΠΌΡΡΠ°ΡΠΈΠΈ JAK2, ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠ΅ΠΉ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½Ρ Π² ΠΊΠΎΡΡΠ½ΠΎΠΌ ΠΌΠΎΠ·Π³Π΅, ΠΈ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΡΠΉ Π΄Π»Ρ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ Π΄ΠΈΠ°Π³Π½ΠΎΠ·Π° ΠΏΠΎ ΠΊΡΠΈΡΠ΅ΡΠΈΡΠΌ ΠΠΠ 2008 ΡΡΠΎΠ²Π΅Π½Ρ ΠΠ¬. Π¦Π΅Π»ΡΡ Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»Π° ΠΎΡΠ΅Π½ΠΊΠ° ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° Π½Π° ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π΅ ΡΡΠ΅ΠΏΠ°Π½ΠΎΠ±ΠΈΠΎΠΏΡΠ°ΡΠΎΠ² ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΌΠ°ΡΠΊΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΠΎΠΉ ΠΠ. ΠΠ΅ΡΠΎΠ΄Ρ. ΠΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
Π΄Π°Π½Π½ΡΡ
ΠΏΡΠΈ Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΌ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠΈ, ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π΄ΠΈΠ°Π³Π½ΠΎΠ·Π°, Π΄Π°Π½Π½ΡΡ
ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»Π° ΡΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½Π° Π³ΡΡΠΏΠΏΠ° ΠΈΠ· 24 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΌΠ°ΡΠΊΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΠ. Π‘ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΠΎΠ³ΠΎ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΊΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΎΡΠ° ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡ Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠ΅ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΡΡ
ΡΡΠ΅ΠΏΠ°Π½ΠΎΠ±ΠΈΠΎΠΏΡΠ°ΡΠΎΠ² ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π°. ΠΡΠΈ ΠΎΡΠ΅Π½ΠΊΠ΅ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΠ΅ΡΠΈΠΊΡΠ»ΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠΈΠ±ΡΠΎΠ·Π° ΡΡΠ΅Π·Ρ ΠΎΠΊΡΠ°ΡΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ ΠΠΎΠΌΠΎΡΠΈ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΠΡΠΈ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΡΡΠ΅ΠΏΠ°Π½ΠΎΠ±ΠΈΠΎΠΏΡΠ°ΡΠΎΠ² ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° Π² Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π΅ ΡΠ»ΡΡΠ°Π΅Π² ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΡΡ Π³ΠΈΠΏΠ΅ΡΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΉ (ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ½ΠΎΠΉ Π½ΠΎΡΠΌΡ) ΠΊΠΎΡΡΠ½ΡΠΉ ΠΌΠΎΠ·Π³ 18/24 (75%). ΠΠΎ Π²ΡΠ΅Ρ
ΡΠ»ΡΡΠ°ΡΡ
Π²ΡΡΠ²Π»Π΅Π½Π° ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΡ ΠΌΠ΅Π³Π°ΠΊΠ°ΡΠΈΠΎΡΠΈΡΠΎΠ², ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ½ΡΡ
ΠΏΠΎ ΡΠ°Π·ΠΌΠ΅ΡΡ ΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΠΈ, Ρ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ Π°ΡΠΈΠΏΠΈΡΠ½ΡΡ
ΡΠΎΡΠΌ Ρ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π³ΠΌΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌΠΈ ΡΠ΄ΡΠ°ΠΌΠΈ, ΡΠΎ Π·ΡΠ΅Π»ΠΎΠΉ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΠ΅ΠΉ. Π Π°ΡΡΠΈΡΠ΅Π½ΠΈΠ΅ ΠΈ ΠΎΠΌΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ ΡΡΠΈΡΡΠΎΠΈΠ΄Π½ΠΎΠ³ΠΎ ΡΠΎΡΡΠΊΠ° Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΎΡΡ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ Π² 23/24 ΠΈ 22/24 ΡΠ»ΡΡΠ°ΡΡ
(95,9% ΠΈ 91,7%). ΠΡΠΈ ΠΎΡΠ΅Π½ΠΊΠ΅ Π³ΠΈΡΡΠΎΡΠΎΠΏΠΎΠ³ΡΠ°ΡΠΈΠΈ ΠΌΠ΅Π³Π°ΠΊΠ°ΡΠΈΠΎΡΠΈΡΠΎΠ² Π² Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π΅ ΡΠ»ΡΡΠ°Π΅Π² 20/24 (83,3%) ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΎΡΡ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ ΡΠ°Π·ΡΠΎΠ·Π½Π΅Π½Π½ΠΎΠ³ΠΎ ΡΠ°ΡΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ ΠΌΠ΅Π³Π°ΠΊΠ°ΡΠΈΠΎΡΠΈΡΠΎΠ² ΠΈ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΡ
Π»ΡΡ
ΠΊΠ»Π°ΡΡΠ΅ΡΠΎΠ² (3-16 ΠΊΠ»Π΅ΡΠΎΠΊ). Π₯Π°ΡΠ°ΠΊΡΠ΅ΡΠ½Π°Ρ Π΄Π»Ρ ΠΈΡΡΠΈΠ½Π½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΡΠΈΡΠ΅ΠΌΠΈΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡ ΡΠ»Π΅ΠΌΠ΅Π½ΡΠΎΠ² ΠΌΠ΅Π³Π°ΠΊΠ°ΡΠΈΠΎΡΠΈΡΠ°ΡΠ½ΠΎΠ³ΠΎ ΡΠΎΡΡΠΊΠ° Π½Π°Π±Π»ΡΠ΄Π°Π»Π°ΡΡ Π² Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π΅ ΡΠ»ΡΡΠ°Π΅Π² 19/24 (79,2%). Π 5/24 (20,8) ΡΠ»ΡΡΠ°Π΅Π² Π±ΡΠ»ΠΈ Π²ΡΡΠ²Π»Π΅Π½Ρ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΡΠ΅ Π΄Π»Ρ ΡΡΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠ΅ΠΌΠΈΠΈ (Β«ΠΠ’-likeΒ» ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ). Π‘ΡΠ΅ΠΏΠ΅Π½Ρ ΡΠΈΠ±ΡΠΎΠ·Π° ΡΡΡΠΎΠΌΡ Π²ΠΎ Π²ΡΠ΅Ρ
ΡΠ»ΡΡΠ°ΡΡ
ΡΠΎΡΡΠ°Π²Π»ΡΠ»Π° MF-0. ΠΡΠ²ΠΎΠ΄Ρ: ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΊΠ°ΡΡΠΈΠ½Π° ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΌΠ°ΡΠΊΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΠΎΠΉ ΠΠ Π² Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π΅ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π½Π°ΠΌΠΈ ΡΠ»ΡΡΠ°Π΅Π² Π±ΡΠ»Π° Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΠΎΠΉ Π΄Π»Ρ ΠΈΡΡΠΈΠ½Π½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΡΠΈΡΠ΅ΠΌΠΈΠΈ. ΠΠΌΠ΅ΡΡΠ΅ Ρ ΡΠ΅ΠΌ, Π² ΡΠ°ΡΡΠΈ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠΉ ΠΏΡΠΈ ΠΌΠ°ΡΠΊΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΠ Π² ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ Π³ΠΈΡΡΠΎΡΠΎΠΏΠΎΠ³ΡΠ°ΡΠΈΠΈ ΠΌΠ΅Π³Π°ΠΊΠ°ΡΠΈΠΎΡΠΈΡΠ°ΡΠ½ΠΎΠ³ΠΎ ΡΠΎΡΡΠΊΠ° ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈΡΡ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΡΠ΅ Π΄Π»Ρ ΡΡΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠ΅ΠΌΠΈΠΈ ΠΈΠ»ΠΈ ΠΏΡΠ΅-ΡΠΈΠ±ΡΠΎΠ·Π½ΠΎΠΉ/ΡΠ°Π½Π½Π΅ΠΉ ΡΡΠ°Π΄ΠΈΠΈ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠ³ΠΎ ΠΌΠΈΠ΅Π»ΠΎΡΠΈΠ±ΡΠΎΠ·Π°
Diagnostics and treatment challenges of Ph-like acute lymphoblastic leukemia: a description of 3 clinical cases
B-cell acute lymphoblastic leukemia (B-ALL) is a diverse group of malignant blood disorders both with regard to the biological properties of the tumor and to therapeutic approaches. Immunophenotyping, molecular genetic techniques, whole-genome sequencing characterize B-ALL as a very diverse group for sensitivity to chemotherapy and prognosis. We present three clinical cases of patients with B-ALL and expected good response to standard therapy, in whom standard protocol treatment failured: refractoriness, persistence of minimal residual disease (MRD), and progression (MRD increase). The remission in these patients was achieved after chemotherapy change to immunological targeted therapy. Nowadays a unified therapeutic approach to all primary patients of the B-ALL is considered generally outdated. Great efforts are carrying out to develop molecular genetic classifications. The molecular dissection of subtypes of B-ALL goes on, and new protocols for selective treatment with targeting are clearly outlined for each subtype of B-ALL
First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature
Nodal anaplastic ALK-negative large cell lymphoma (nALCL, ALK-) is a Π’-cell lymphoma that is characterized by aggressive clinical course and low sensitivity to Π‘ΠΠΠ (cyclophosphamide, doxorubicin, vincristine, prednisolone) and other chemotherapy regimen. In the article we present a literature review and describe our clinical case of nALCL, ALK-. For the first time a combination of Brentuximab vedotin with modified program NHL-BFM-90 was used as a first-line therapy. As a result of immunochemotherapy a complete antineoplastic effect was obtained. For consolidation of this effect high-dose chemotherapy with following autologous blood stem cell transplantation was performed. The chosen treatment tactics allowed to achieve a complete remission in a medium risk group patient
ΠΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΈ ΡΠ»ΡΡΡΠ°ΡΡΡΡΠΊΡΡΡΠ½Π°Ρ Π²ΠΈΠ·ΡΠ°Π»ΠΈΠ·Π°ΡΠΈΡ ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠ° SARS-CoV-2 Π² ΡΠΊΠ°Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ , Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ·Π»ΠΎΠ² ΠΈ ΠΏΠΎΡΠ΅ΠΊ ΡΠΌΠ΅ΡΡΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²
The objective: immunohistochemical and electron microscopic imaging of the SARS-CoV-2 coronavirus in lung, lymph nodes and kidney tissues of patients who died of COVID-19.Subjects and Methods. For immunohistochemical tests, specimens of sections of formalin-fixed and paraffin-embedded tissues of the lungs, lymph nodes and kidneys of patients who died from COVID-19 were used. Quantitative assessment of the SARS-CoV-2 viral load level was carried by the original RT qPCR and calculated by the formula: SARS-CoV-2 copy number/ABL1 Ρ
100 copies, expressed as the ratio of the true number of SARS-CoV-2 cDNA copies per 100 copies cDNA of the ABL1 gene. For morphological tests, samples of native lung, lymph node and kidney tissues were taken.Results. Immunohistochemical and electron microscopic tests revealed particles of the SARS-CoV-2 coronavirus in the cytoplasm of endothelial cells of air-blood barrier of the lungs, the vascular glomerulus of the kidneys, in the cytoplasm of macrophages of the lymph node, and also in cytoplasm of lymphocytes in the lumen of lung capillaries.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΈ ΡΠ»Π΅ΠΊΡΡΠΎΠ½Π½ΠΎ-ΠΌΠΈΠΊΡΠΎΡΠΊΠΎΠΏΠΈΡΠ΅ΡΠΊΠ°Ρ Π²ΠΈΠ·ΡΠ°Π»ΠΈΠ·Π°ΡΠΈΡ ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠ° SARS-CoV-2 Π² ΡΠΊΠ°Π½ΡΡ
Π»Π΅Π³ΠΊΠΈΡ
, Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»ΠΎΠ² ΠΈ ΠΏΠΎΡΠ΅ΠΊ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΡΠΌΠ΅ΡΡΠΈΡ
ΠΎΡ COVID-19.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ»Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π° ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ ΡΡΠ΅Π·Ρ ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π² ΡΠΎΡΠΌΠ°Π»ΠΈΠ½Π΅ ΠΈ Π·Π°ΠΊΠ»ΡΡΠ΅Π½Π½ΡΡ
Π² ΠΏΠ°ΡΠ°ΡΠΈΠ½ ΡΠΊΠ°Π½Π΅ΠΉ Π»Π΅Π³ΠΊΠΈΡ
, Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»ΠΎΠ² ΠΈ ΠΏΠΎΡΠ΅ΠΊ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΡΠΌΠ΅ΡΡΠΈΡ
ΠΎΡ COVID-19. ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½Π°Ρ ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΠΎΠ²Π½Ρ Π²ΠΈΡΡΡΠ½ΠΎΠΉ Π½Π°Π³ΡΡΠ·ΠΊΠΈ SARS-CoV-2 ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΎΡΠΈΠ³ΠΈΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΏΠΎΡΠΎΠ±Π° ΠΊΠΠ¦Π Π Π ΠΈ ΡΠ°ΡΡΡΠΈΡΠ°Π½Π° ΠΏΠΎ ΡΠΎΡΠΌΡΠ»Π΅: ΡΠΈΡΠ»ΠΎ ΠΊΠΎΠΏΠΈΠΉ SARS-CoV-2/ΡΠΈΡΠ»ΠΎ ΠΊΠΎΠΏΠΈΠΉ ABL1 Ρ
100, Π²ΡΡΠ°ΠΆΠ΅Π½Π° ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΈΡΡΠΈΠ½Π½ΠΎΠ³ΠΎ ΡΠΈΡΠ»Π° ΠΊΠΎΠΏΠΈΠΉ ΠΊΠΠΠ SARS-CoV-2 Π½Π° 100 ΠΊΠΎΠΏΠΈΠΉ ΠΊΠΠΠ Π³Π΅Π½Π° ABL1. ΠΠ»Ρ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π²Π·ΡΡΡ Π½Π°ΡΠΈΠ²Π½ΡΠ΅ ΠΎΠ±ΡΠ°Π·ΡΡ ΡΠΊΠ°Π½Π΅ΠΉ Π»Π΅Π³ΠΊΠΈΡ
, Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»ΠΎΠ² ΠΈ ΠΏΠΎΡΠ΅ΠΊ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΈ ΡΠ»Π΅ΠΊΡΡΠΎΠ½Π½ΠΎ-ΠΌΠΈΠΊΡΠΎΡΠΊΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΡΠ°ΡΡΠΈΡΡ ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠ° SARS-CoV-2 Π±ΡΠ»ΠΈ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Ρ Π² ΡΠΈΡΠΎΠΏΠ»Π°Π·ΠΌΠ΅ ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ Π°ΡΡΠΎΠ³Π΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π±Π°ΡΡΠ΅ΡΠ° Π»Π΅Π³ΠΊΠΈΡ
, ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠ³ΠΎ ΠΊΠ»ΡΠ±ΠΎΡΠΊΠ° ΠΏΠΎΡΠ΅ΠΊ, Π² ΡΠΈΡΠΎΠΏΠ»Π°Π·ΠΌΠ΅ ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ² Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ·Π»Π°, Π° ΡΠ°ΠΊΠΆΠ΅ Π² ΡΠΈΡΠΎΠΏΠ»Π°Π·ΠΌΠ΅ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² Π² ΠΏΡΠΎΡΠ²Π΅ΡΠ΅ ΠΊΠ°ΠΏΠΈΠ»Π»ΡΡΠΎΠ² Π»Π΅Π³ΠΊΠΈΡ
Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation
Objective. To analyze treatment results of 172 patients with acute myeloid leukemia (AML) aged 18-60 years in National Medical Research Center for Hematology of MHRF. Materials and methods. Inductive and consolidation program for 139 (80%) patients was based on a standardized protocol: 4 courses β7+3β with different anthracycline use (2 courses of daunorubicin, idarubicin, mitoxantrone) and continuous use of cytarabine on the second inductive course. In 20% of patients cytarabine courses at the dose of 1 g/m2 2 times a day for 1-3 days combined with idarubicin and mitoxantrone were used as two consolidation courses. Allogenic bone marrow transplantation was performed in the first complete remission (CR) period in 40% of patients. Results. The frequency of CR achievement in all patients was 78.6%, refractory forms were observed in 13.9% of patients, early mortality - in 7.5% of patients. Seven-year overall survival (OS) rate was 40.7%, relapse free survival (RFS) - 43.2%. When estimating effectiveness depending on cytogenetic risk group it was demonstrated that 5-year OS and RFS in patients with translocation (8; 21) cannot be considered as satisfying, it accounted for 50 and 34%, respectively. At the same time in patients with 16th chromosome inversion (inv16) these characteristics accounted for 68.6 and 63.5%. Acquired results forced reconsidering of the consolidation program in AML patients of this subgroup. The median time to allogenic blood stem cells transplantation (allo-BSCT) in patients with first CR was 6.5 months that was taken as a reference point in landmark analysis of patients in whom allo-BSCT was not performed. Landmark analysis showed that in AML patients of favorable prognosis group allo-BSCT does not significantly reduce the probability of relapse (0 and 36%) and does not influence RFS (33 and 64%). In patients of border-line and poor prognosis allo-BSCT significantly reduces relapse probability (26 and 66%; 20 and 100%) and significantly increases a 7-year RFS (68.7 and 30%; 45.6 and 0%). Allo-BSCT also results in significant RFS increase and reduces the probability of relapse (25 and 78%) in patients in whom CR was achieved only after the second induction course. At the same time allo-BSCT does not influence patients who achieved CR after the first treatment course: 55 and 50%. Conclusion. Multivariate analysis showed that cytogenetic risk group (HR=2.3), time of CR achievement (HR=2.9), and allo-BSCT transplantation (HR=0.16) are independent factors for disease relapse prognosis after achieving CR
BRAF and MAP2K1 mutations in hairy cell leukemia and splenic marginal zone B-cell lymphoma
DNA samples from patients with hairy cell leukemia (HCL) and splenic marginal zone B-cell lymphoma (MZBCL) for BRAF andΒ MAP2K1 activating mutations were analyzed. V600E mutation of BRAF was detected in 39 (98 %) of 40 patients with hairy cell leukemia,Β and no patient with MZBCL. In none of the patients in this study any other activating mutations than V600E in exons 11 and 15Β of BRAF gene were revealed. MAP2K1 Q56P mutation characterized by IGHV4-34 expression was detected in 1 (2 %) of 40 patients withΒ HCL. In none of the patients with MZBCL activating mutations in the 2, 3 or 11 exons of MAR2K1 gene have been identified, includingΒ those with IGHV4-34 expression